Evidence map›Paper›PMID 39070181›Full record

ReviewMedComm2024

The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics.

Jian Tang, Yu Chen, Chunhua Wang, Ying Xia, Tingyu Yu, Mengjun Tang, Kun Meng, Lijuan Yin, Yang Yang, Liang Shen and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in MedComm, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. AnOncology research · 2026
    Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jian TangCentral Laboratory Xiangyang Central Hospital Affiliated Hospital of Hubei University of Arts and Science Xiangyang China.
Yu ChenCentral Laboratory Xiangyang Central Hospital Affiliated Hospital of Hubei University of Arts and Science Xiangyang China.
Chunhua WangDepartment of Clinical Laboratory Xiangyang No. 1 People's Hospital Hubei University of Medicine Xiangyang Hubei Province China.
Ying XiaCentral Laboratory Xiangyang Central Hospital Affiliated Hospital of Hubei University of Arts and Science Xiangyang China.
Tingyu YuCentral Laboratory Xiangyang Central Hospital Affiliated Hospital of Hubei University of Arts and Science Xiangyang China.
Mengjun TangCentral Laboratory Xiangyang Central Hospital Affiliated Hospital of Hubei University of Arts and Science Xiangyang China.
Kun MengCentral Laboratory Xiangyang Central Hospital Affiliated Hospital of Hubei University of Arts and Science Xiangyang China.
Lijuan YinState Key Laboratory of Food Nutrition and Safety Key Laboratory of Industrial Microbiology Ministry of Education Tianjin Key Laboratory of Industry Microbiology National and Local United Engineering Lab of Metabolic Control Fermentation Technology China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry College of Biotechnology Tianjin University of Science & Technology Tianjin China.
Yang YangShenzhen Key Laboratory of Pathogen and Immunity National Clinical Research Center for Infectious Disease State Key Discipline of Infectious Disease Shenzhen Third People's Hospital Second Hospital Affiliated to Southern University of Science and Technology Shenzhen China.
Liang ShenCentral Laboratory Xiangyang Central Hospital Affiliated Hospital of Hubei University of Arts and Science Xiangyang China.
Hui XingCentral Laboratory Xiangyang Central Hospital Affiliated Hospital of Hubei University of Arts and Science Xiangyang China.
Xiaogang MaoCentral Laboratory Xiangyang Central Hospital Affiliated Hospital of Hubei University of Arts and Science Xiangyang China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) are recruited by malignant tumor cells to the tumor microenvironment (TME) and play a crucial role in the initiation and progression of malignant tumors. This role encompasses immune evasion, promotion of angiogenesis, stimulation of cancer cell proliferation, correlation with cancer stem cells, multilineage differentiation within the TME, and development of treatment resistance. Simultaneously, extensive research is exploring the homing effect of MSCs and MSC-derived extracellular vesicles (MSCs-EVs) in tumors, aiming to design them as carriers for antitumor substances. These substances are targeted to deliver antitumor drugs to enhance drug efficacy while reducing drug toxicity. This paper provides a review of the supportive role of MSCs in tumor progression and the associated molecular mechanisms. Additionally, we summarize the latest therapeutic strategies involving engineered MSCs and MSCs-EVs in cancer treatment, including their utilization as carriers for gene therapeutic agents, chemotherapeutics, and oncolytic viruses. We also discuss the distribution and clearance of MSCs and MSCs-EVs upon entry into the body to elucidate the potential of targeted therapies based on MSCs and MSCs-EVs in cancer treatment, along with the challenges they face.

Indexed as

drug deliverymesenchymal stem cellstumor microenvironmenttumor‐targeted therapy

Identifiers

PMID39070181
PMCPMC11283587

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.